Our findings in the present trial [and in the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE)30 and the Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin‐Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM‐HF)31] contrast with those recently described in the VICTORIA trial which enrolled sicker patients who had recently been hospitalized. This evidence concerns the gene MME and heart failure.